The estimated Net Worth of David Scadden is at least $429 ezer dollars as of 13 June 2024. David Scadden owns over 3,388 units of Editas Medicine Inc stock worth over $58,526 and over the last 7 years he sold EDIT stock worth over $0. In addition, he makes $370,652 as Independent Director at Editas Medicine Inc.
David has made over 7 trades of the Editas Medicine Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 3,388 units of EDIT stock worth $12,807 on 13 June 2024.
The largest trade he's ever made was buying 6,600 units of Editas Medicine Inc stock on 25 June 2018 worth over $99,000. On average, David trades about 812 units every 91 days since 2017. As of 13 June 2024 he still owns at least 15,483 units of Editas Medicine Inc stock.
You can see the complete history of David Scadden stock trades at the bottom of the page.
Dr. David T. Scadden M.D. serves as Independent Director of the Company. Dr. Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University, a position he has held since 2006. Since 1995, Dr. Scadden has practiced at the Massachusetts General Hospital, where he founded and directs the Center for Regenerative Medicine and directed the Hematologic Malignancies Center of the MGH Cancer Center for 10 years. Dr. Scadden co-founded and co-directs the Harvard Stem Cell Institute and is Chairman emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. He is a member of the National Academy of Medicine and the American Academy of Arts and Sciences and a Fellow of the American College of Physicians and the American Academy for the Advancement of Science. He is a former affiliate member of the Broad Institute of Harvard and the Massachusetts Institute of Technology and is a former member of the Board of External Experts for the National Heart, Lung and Blood Institute, the Board of Scientific Counselors for the National Cancer Institute and Board of Directors of the International Society for Stem Cell Research. Dr. Scadden has served on the boards of Agios since May 2017 and Magenta Therapeutics, Inc., a public biotechnology company, since November 2016, where he is a scientific founder, and private biotechnology companies LifeVault Bio and Clear Creek Bio, Inc. since May 2017 and February 2017, respectively, and is a scientific founder of Fate Therapeutics, Inc., a public biotechnology company. Dr. Scadden holds a B.A. from Bucknell University in English, an M.D. from Case Western Reserve University and holds honorary degrees, including an A.M. from Harvard Medical School, an Sc.D. from Bucknell University, D. Sci from Case Western Reserve University and an M.D. from Lund University in Sweden. Scadden is qualified to serve on our Board due to his scientific expertise in the fields of hematology and oncology.
As the Independent Director of Editas Medicine Inc, the total compensation of David Scadden at Editas Medicine Inc is $370,652. There are 4 executives at Editas Medicine Inc getting paid more, with Cynthia Collins having the highest compensation of $14,489,700.
David Scadden is 67, he's been the Independent Director of Editas Medicine Inc since 2019. There are no older and 16 younger executives at Editas Medicine Inc.
David's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr és Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine Inc executives and other stock owners filed with the SEC include: